x

Posted 27 October, 2022

Merck & Co., Inc. appointed new CEO

CEO Change detected for ticker NYSE:MRK in a 8-K filed on 27 October, 2022.


  In addition, on October 26, 2022, the Board unanimously elected Robert M. Davis, Merck's current Chief Executive Officer and President as well as a Director on the Board to serve as Chairman of the Board, effective December 1, 2022.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Merck & Co., Inc.
Health Care/Life Sciences • Pharmaceuticals
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Market Cap
$314B
View Company Details
Merck & Co., Inc. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangment of Certiain Officers.


(b) Merck announced that Kenneth C. Frazier, the Executive Chairman of Merck's Board of Directors (the "Board") will retire from the Board, effective November 30, 2022. 


In addition, on October 26, 2022, the Board unanimously elected Robert M. Davis, Merck's current Chief Executive Officer and President as well as a Director on the Board to serve as Chairman of the Board, effective December 1, 2022.


On October 26, 2022, the Company issued a press release announcing the foregoing. The press release is attached as Exhibit 99.3 and incorporated herein by reference.